RxDoctor Payments Data

Kyle Frick, MD

Cardiovascular Disease · Avon, INNPI 1912290925

Payments from drug & device makers

$1,569in general payments, 2019–2025

Across 68 payments — averaging $23.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$508
  • Abbott$326
  • AstraZeneca$99
  • Medtronic$97
  • Amgen$93
  • E.r. Squibb & Sons, L.L.C.$75
  • plus $371 from 11 others

What the payments were for

  • Food & beverage$1,55599%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,569 in reported general payments places this provider in the 40th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$112,288
Medicare patients
731
Services billed
1,368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban222$265,343
XareltoRivaroxaban61$71,034
EntrestoSacubitril/Valsartan31$55,234
Repatha SureclickEvolocumab57$54,456
JardianceEmpagliflozin22$31,016
BrilintaTicagrelor25$30,108
FarxigaDapagliflozin Propanediol16$27,966
OzempicSemaglutide19$25,847
VascepaIcosapent Ethyl22$10,422
Ranolazine ErRanolazine48$8,321
Rosuvastatin Calcium242$6,511
Atorvastatin Calcium461$5,038
Metoprolol Succinate283$3,562
Torsemide79$2,198
Ezetimibe104$1,893

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$73$265,343222 claims
Johnson & JohnsonXarelto$35$71,03461 claims
AstraZenecaBrilinta, Farxiga$99$58,07441 claims
Novo NordiskOzempic$42$25,84719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Avon

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →